OBJECTIVES:
Primary
* Determine event-free survival of patients with large B-cell lymphoma treated with CHOP-R followed by consolidation therapy.
Secondary
* Determine overall survival.
* Evaluate relapse-free survival for patients achieving complete or partial response.
* Determine the rate of disease progression.
* Determine response rate at the end of study therapy.
* Assess the toxicities of this regimen.
OUTLINE: This is a multicenter study.
* Induction therapy: Patients receive the CHOP-R regimen comprising doxorubicin hydrochloride IV, vincristine IV, cyclophosphamide IV, and rituximab IV on day 1 and prednisone IV on days 1-5. Treatment repeats every 2 weeks for 2 courses.
Patients who achieve complete or partial response, as assessed by PET/CT scan, receive a third course of induction therapy.
* Consolidation therapy: Patients receive rituximab IV on days -8 to 0 and yttrium Y 90 ibritumomab tiuxetan IV on day 0.
